Analyzing Genelux (NASDAQ:GNLX) & Q32 Bio (NASDAQ:QTTB)

Genelux (NASDAQ:GNLX) and Q32 Bio (NASDAQ:QTTB) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, profitability and valuation.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Genelux and Q32 Bio, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genelux	1	0	2	1	2.75
Q32 Bio	1	1	6	1	2.78

Genelux currently has a consensus price target of $20.00, suggesting a potential upside of 952.63%. Q32 Bio has a consensus price target of $32.17, suggesting a potential upside of 264.70%. Given Genelux’s higher possible upside, research analysts plainly believe Genelux is more favorable than Q32 Bio.

Profitability

This table compares Genelux and Q32 Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Genelux	N/A	-205.85%	-138.79%
Q32 Bio	N/A	17.03%	15.24%

Institutional and Insider Ownership

37.3% of Genelux shares are owned by institutional investors. Comparatively, 31.3% of Q32 Bio shares are owned by institutional investors. 7.5% of Genelux shares are owned by company insiders. Comparatively, 34.5% of Q32 Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Genelux and Q32 Bio”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genelux	$10,000.00	8,595.60	-$32.15 million	($0.86)	-2.21
Q32 Bio	$53.74 million	4.91	$29.82 million	$3.34	2.64

Q32 Bio has higher revenue and earnings than Genelux. Genelux is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Genelux has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500. Comparatively, Q32 Bio has a beta of 0.45, indicating that its share price is 55% less volatile than the S&P 500.

Summary

Q32 Bio beats Genelux on 9 of the 13 factors compared between the two stocks.

About Genelux

Genelux Corporation is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer. The company’s lead product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, genetically modified oncolytic vaccinia virus designed to selectively infect and destroy tumor cells while stimulating an immune response against cancer. Genelux is evaluating Olvi-Vec in combination with other treatments across multiple solid-tumor indications. Its clinical development efforts have included ovarian cancer, where the candidate is being studied in patients with advanced or recurrent disease, as well as other potential applications in cancers such as colorectal and lung cancer.

About Q32 Bio

Q32 Bio is a biotechnology company focused on developing treatments for autoimmune and inflammatory diseases by targeting pathways that regulate the immune system. Its research has centered on biologic medicines designed to restore immune balance and address disease mechanisms. The company’s programs have included ADX-097, a complement C3 inhibitor designed to target activity in affected tissues, and ADX-914, an antibody targeting the interleukin-7 receptor alpha. Q32 Bio has been based in the United States and has advanced its programs through clinical development.